US BioTek Laboratories, a Seattle-based functional laboratory specializing in advanced immunological and integrative diagnostics, has completed its merger with Australian functional pathology provider NutriPATH Pathology, marking a significant expansion of its global footprint in personalized and root-cause-focused healthcare testing.
The transaction brings together two organizations known for their focus on clinical relevance, scientific rigor, and practitioner support within the functional and integrative medicine space. The combined entity aims to broaden international access to comprehensive, clinically actionable testing solutions for healthcare providers worldwide.
US BioTek Laboratories has built its reputation on immune reactivity, food sensitivity, toxin analysis, and specialty biomarker testing, delivering data-driven insights to integrative and personalized healthcare practitioners. NutriPATH Pathology, based in Melbourne, is recognized for its functional pathology expertise, including gut health diagnostics, nutritional assessment, hormone analysis, and metabolic marker testing.
Together, the companies plan to offer an expanded testing portfolio designed to support personalized, root-cause-centered care while maintaining strong educational and clinical support for practitioners.
NutriPATH Pathology will continue operating under its established brand in Australia, ensuring continuity for its existing practitioner base. However, the company will gain access to additional resources, technologies, and collaborative scientific development capabilities through the combined organization. Both companies emphasized that clients can expect a seamless transition and continued commitment to service excellence.
The merger represents a strategic alignment intended to strengthen innovation, improve global access to functional laboratory testing, and enhance support for clinicians focused on integrative and functional medicine.
KEY QUOTES
“This merger marks an exciting new chapter for both US BioTek and NutriPATH. Our shared philosophy centers on providing clinicians with meaningful data they can trust and apply in practice. By bringing our teams and capabilities together, we are strengthening our ability to support practitioners with deeper insights, improved access, and expanded innovation.”
Jack Frausing, CEO of US BioTek Laboratories
“This is more than a combination of two companies — it is a strategic alignment of values, scientific expertise, and a mutual dedication to advancing functional medicine globally.”
James Cavaggion, CEO of NutriPATH
